Patents Assigned to 1Globe Health Institute LLC
  • Therapeutics for central nervous system disorders
    Patent number: 11370748
    Abstract: The invention provides novel compounds, pharmaceutical compositions and methods of preparation and use thereof for treating disease affecting the central nervous system such as multiple sclerosis.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: June 28, 2022
    Assignees: 1GLOBE BIOMEDICAL CO., LTD., 1GLOBE HEALTH INSTITUTE LLC
    Inventors: Chiang J. Li, Suzhen Chen, Jifeng Liu
  • Compositions of asymmetric interfering RNA and uses thereof
    Patent number: 11015195
    Abstract: The present invention provides asymmetrical duplex RNA molecules that are capable of effecting sequence-specific gene silencing. The RNA molecule comprises a first strand and a second strand. The first strand is longer than the second strand. The RNA molecule comprises a double-stranded region formed by the first strand and the second strand, and two ends independently selected from the group consisting of 5?-overhang, 3?-overhang, and blunt end. The RNA molecules of the present invention can be used as research tools and/or therapeutics.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: May 25, 2021
    Assignee: 1GLOBE HEALTH INSTITUTE LLC
    Inventors: Chiang Jia Li, Xiangao Sun, Harry Rogoff, Youzhi Li
  • Biodegradable and clinically-compatible nanoparticles as drug delivery carriers
    Patent number: 11001840
    Abstract: The present invention relates to the composition of a nanoparticle based on a magnesium salt, and methods of drug delivery using the nanoparticle. A preferred embodiment uses magnesium phosphate, with or without a shell to deliver aiRNA and/or siRNA. The nanoparticles of the present invention are also effective when administered orally.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: May 11, 2021
    Assignee: 1GLOBE HEALTH INSTITUTE LLC
    Inventors: Chiang Jia Li, Youzhi Li, Keyur Gada, Xiaoshu Dai
  • Compositions of asymmetric interfering RNA and uses thereof
    Patent number: 10927376
    Abstract: The present invention provides asymmetrical duplex RNA molecules that are capable of effecting sequence-specific gene silencing. The RNA molecule comprises a first strand and a second strand. The first strand is longer than the second strand. The RNA molecule comprises a double-stranded region formed by the first strand and the second strand, and two ends independently selected from the group consisting of 5?-overhang, 3?-overhang, and blunt end. The RNA molecules of the present invention can be used as research tools and/or therapeutics.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: February 23, 2021
    Assignee: 1GLOBE HEALTH INSTITUTE LLC
    Inventors: Chiang Jia Li, Xiangao Sun, Harry Rogoff, Youzhi Li
  • Compositions of asymmetric interfering RNA and uses thereof
    Patent number: 10266821
    Abstract: The present invention provides asymmetrical duplex RNA molecules that are capable of effecting sequence-specific gene silencing. The RNA molecule comprises a first strand and a second strand. The first strand is longer than the second strand. The RNA molecule comprises a double-stranded region formed by the first strand and the second strand, and two ends independently selected from the group consisting of 5?-overhang, 3?-overhang, and blunt end. The RNA molecules of the present invention can be used as research tools and/or therapeutics.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: April 23, 2019
    Assignee: 1GLOBE HEALTH INSTITUTE LLC
    Inventors: Chiang Jia Li, Xiangao Sun, Harry Rogoff, Youzhi Li
  • Compositions of asymmetric interfering RNA and uses thereof
    Patent number: 9328345
    Abstract: The present invention provides asymmetrical duplex RNA molecules that are capable of effecting sequence-specific gene silencing. The RNA molecule comprises a first strand and a second strand. The first strand is longer than the second strand. The RNA molecule comprises a double-stranded region formed by the first strand and the second strand, and two ends independently selected from the group consisting of 5?-overhang, 3?-overhang, and blunt end. The RNA molecules of the present invention can be used as research tools and/or therapeutics.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: May 3, 2016
    Assignee: 1 GLOBE HEALTH INSTITUTE LLC
    Inventors: Chiang Jia Li, Xiangao Sun, Harry Rogoff, Youzhi Li
  • BIODEGRADABLE AND CLINICALLY-COMPATIBLE NANOPARTICLES AS DRUG DELIVERY CARRIERS
    Publication number: 20160046936
    Abstract: The present invention relates to the composition of a nanoparticle based on a magnesium salt, and methods of drug delivery using the nanoparticle. A preferred embodiment uses magnesium phosphate, with or without a shell to deliver aiRNA and/or siRNA. The nanoparticles of the present invention are also effective when administered orally.
    Type: Application
    Filed: February 5, 2014
    Publication date: February 18, 2016
    Applicant: 1Globe Health Institute LLC
    Inventors: Chiang Jia Li, Youzhi Li, Keyur Gada, Xiaoshu Dai